On May 26, 2020, President Trump announced a new model for Medicare Part D enrollees who purchase insulin. This model will begin on January 1, 2021. It is designed to help 3.3 million Americans affordably access insulin by capping the cost of a 30-day supply for most insulins to a maximum of $35. For enrollees who choose a model participating plan, their insulin prescription will not be subject to a deductible or any coverage gap cost increases. (Whether it’s January or December, their monthly out-of-pocket cost for insulin will be $35 or less.)
Which insulins might offer lower costs? The medications listed below would have a $35 copay, and not have to meet an upfront deductible, and does not increase in cost during the full year! This is really good. Call me (Stephen Merrill 949-584-2634) There are Medicare Advantage HMO plans that will be participating too.